Launching a clinical trial for a drug intended to treat severe asthma during a respiratory pandemic — particularly one that seems to hit people with some types of asthma particularly hard — could be a risky move.
Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine.
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced today that Rajesh (Raj) Devraj, PhD, is joining the firm as a venture partner. Devraj will be working with the Atlas team to identify and execute upon compelling opportunities for new biotechnology company creation.
Cyrus Mozayeni got excited when he began to explore the academic work of Ehud Isacoff and John G. Flannery at UC Berkeley.
In a recent blog post, I walked through my tips for reading your adversaries’ body language while maintaining your own poker face throughout negotiations.
In this second post, I’ll share practical tactics for gaining leverage and using it wisely. Women of biotech, there’s also a special section for you – so read on!
By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC.